ロード中...
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
BACKGROUND: The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers. FDR gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical eff...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2006
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1402306/ https://ncbi.nlm.nih.gov/pubmed/16504126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-42 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|